Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.75
(
-0.90%
)
Bitcoin
74,299.86
(
0.48%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 119058

Thursday, 04/28/2011 9:49:22 PM

Thursday, April 28, 2011 9:49:22 PM

Post# of 257253

PFE—Didn't mention anything on how Humira arm was doing.

It would be nice to know how Tofacitinib did compared to Humira, but the comparison to placebo was technically the primary endpoint in ORAL Standard (http://clinicaltrials.gov/ct2/show/NCT00853385 ). I’m not sure we can infer anything about the Humira arm from the top-line data reported in today’s PR.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now